MARBURG, Germany, Nov. 17 /PRNewswire/ -- vectron therapeutics AG today announced that it has designated a clinical candidate VTN-706. VTN-706 is a chemotherapeutic based on a proprietary delivery system that will enter formal preclinical development this year. The company has also recently named Dr. Petra Wuelfroth as Chief Executive Officer and Mr. Axel H. Leimer as Chief Business Officer. Dr. Wuelfroth and Mr. Leimer form the new executive board of vectron.
"We are pleased to have won Dr. Wuelfroth and Mr. Leimer for vectron," said Michael Wrede, Chairman of the Supervisory Board. "vectron is turning its research in targeted tumor-therapy into clinical candidates in two of the company's programmes. Dr. Wuelfroth and Mr. Leimer bring the experience necessary to lead the company into product development and successful partnerships."
VTN-706 is the first of a class of chemotherapeutics for the treatment of life-threatening cancers with vectron's proprietary delivery technology. With this formulation the efficacy of anti-neoplastics was improved significantly in preclinical models. vectron intends to bring other compounds forward or contribute to improving proprietary compounds of partners.
Dr. Wuelfroth has more than 15 years of international business experience in the pharmaceutical industry and in consulting. In 1998 she founded "International Pharma Consulting." She has served as interim CTO/CEO for vasopharmBIOTECH and has held a number of positions in R&D management in medium-sized and multinational pharmaceutical companies in Germany and Japan. Dr. Wulfroth studied pharmacy and earned her Ph.D. at the German-Cancer- Research-Center in Heidelberg.
Mr. Leimer has worked 17 years at a national bank and leading biotech companies in the US. He has held positions as director of business operations, clinical networks and manager for early research through phase 1 projects. Most recently he was managing director of a pharmaco-genomics company and currently serves as investment advisor to Future Capital. Mr. Leimer graduated with a master degree in biochemistry from the University of Colorado.
vectron will present on Tuesday, November 18th, at the BioEurope 2003.
vectron therapeutics AG is developing targeted chemotherapeutics and therapeutic vaccines for cancer. vectron applies its proprietary delivery technology to improve pharmaco-kinetics and targeting of cancer drugs. vectron is located in Marburg, Germany and was founded in 2000. vectron is recipient of a BioChance grant from the German Government.
vectron therapeutics AG
CONTACT: Birgit Meister of vectron, +49-6421-3099-0,Fax: +49-6421-3099-13, email@example.com